Holen Sie sich die Stockscreener-App
4.36
7.82%
-0.37
Handel nachbörslich:
4.01
-0.35
-8.03%
Scisparc Ltd Aktie (SPRC) Neueste Nachrichten
SciSparc Subsidiary NeuroThera to Take Majority Stake in Quantum Trials Firm CliniQuantum - TipRanks
SciSparc’s Neurothera Labs announces publication of international patent - TipRanks
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Bitget
SciSparc Ltd. Advances Collaboration with NeuroThera Labs Inc. and Clearmind Medicine Inc. for Novel Combination Therapy Targeting Obesity and MASLD. - Quiver Quantitative
SciSparc: NeuroThera Labs Announces Publication of - GlobeNewswire
SciSparc: $9.46 Million NeuroThera Deal To Acquire Majority Stake In Quantum Clinical Trials Firm CliniQuantum - Pulse 2.0
SciSparc, Subsidiary NeuroThera Labs Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails - marketscreener.com
NeuroThera to acquire 54% stake in quantum tech firm CliniQ - Investing.com South Africa
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails - Bitget
SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum - TipRanks
SciSparc Ltd. Subsidiary NeuroThera Labs Inc. Enters Share Purchase Agreement to Acquire Majority Stake in CliniQuantum Ltd. - Quiver Quantitative
SciSparc Ltd. (SPRC) Schedule 13G/A amendment shows holder ≤5% - Stock Titan
Can SciSparc Ltd. stock resist market sell offsJuly 2025 Update & Accurate Trade Setup Notifications - Naître et grandir
Aug Reactions: What is the implied volatility of SciSparc LtdEarnings Summary Report & Fast Gain Stock Trading Tips - baoquankhu1.vn
Analyst Upgrade: Whats the beta of SciSparc Ltd stockPortfolio Update Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SciSparc announces 1-for-9 reverse share split - Yahoo Finance
SciSparc to implement 1-for-9 reverse stock split Wednesday - Investing.com India
SPRC Earnings History & Surprises | EPS & Revenue Results | SCISPARC LTD (NASDAQ:SPRC) - ChartMill
SPRC SEC FilingsScisparc 10-K, 10-Q, 8-K Forms - Stock Titan
SciSparc to implement 1-for-9 reverse stock split Wednesday By Investing.com - Investing.com Canada
SciSparc Falls 12% After Announcing 1-for-9 Reverse Share Split - Nasdaq
SciSparc to Enact 1-for-9 Reverse Share Split as Outstanding Shares Shrink - TipRanks
SciSparc (NASDAQ: SPRC) to implement 1-for-9 reverse share split - Stock Titan
SciSparc Announces 1-for-9 Reverse Share Split - GlobeNewswire
SciSparc Amends $10 Million Note Deal, Issues $2 Million Initial Convertible Note - TipRanks
Is SciSparc Ltd. stock safe for conservative investorsShare Buyback & Target Return Focused Stock Picks - mfd.ru
Why SciSparc Ltd. stock remains undervaluedJuly 2025 Rallies & Weekly Market Pulse Alerts - mfd.ru
SPRC PE Ratio & Valuation, Is SPRC Overvalued - Intellectia AI
SciSparc Sets Up $10 Million Convertible Note Facility With Warrants - The Globe and Mail
Can SciSparc Ltd. stock outperform in a bear market2025 Trading Recap & Momentum Based Trading Ideas - mfd.ru
Will SciSparc Ltd. stock benefit from infrastructure spendingProduct Launch & High Accuracy Investment Signals - mfd.ru
Will SciSparc Ltd. stock deliver strong dividend growth2025 Trading Volume Trends & Safe Swing Trade Setups - mfd.ru
SciSparc announces resale of 61.21M shares by selling shareholders; shares down - MSN
Should you avoid Star Equity Holdings Inc stock right nowMarket Movement Recap & Community Trade Idea Sharing - baoquankhu1.vn
SciSparc Shareholders Approve February Governance Agenda - TipRanks
Aug Sentiment: How correlated is SciSparc Ltd to the S P5002025 Earnings Impact & Real-Time Chart Pattern Alerts - baoquankhu1.vn
SciSparc subsidiary receives U.S. patent for antibiotic-enhancing cannabinoid technology - Investing.com Nigeria
SciSparc Subsidiary NeuroThera Wins U.S. Patent for Cannabinoid-Based Antimicrobial Resistance Platform - TipRanks
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome ... - Caledonian Record
SciSparc: NeuroThera Labs Granted U.S. Patent for - GlobeNewswire
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA - The Manila Times
Ideas Watch: What is the target price for SciSparc Ltd stockJuly 2025 Highlights & Target Return Focused Picks - baoquankhu1.vn
Aug Fed Impact: What is SciSparc Ltds TAM Total Addressable MarketMarket Trend Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Entry Recap: Is SciSparc Ltd backed by strong institutional buyingJuly 2025 Update & AI Enhanced Execution Alerts - baoquankhu1.vn
Market Trends: Is SciSparc Ltd part of any ETFWeekly Risk Summary & Verified Chart Pattern Trade Signals - baoquankhu1.vn
SciSparc acquires MUSE system IP portfolio to enter GERD device market - Investing.com Australia
SciSparc acquires MUSE system IP portfolio to enter GERD device market By Investing.com - Investing.com South Africa
SciSparc Closes Acquisition of Xylo GERD Device IP, Moves to Immediate Commercialization - TipRanks
SciSparc Acquires Innovative GERD Device IP Portfolio from Xylo Technologies to Target Multi-Billion Dollar Market - Quiver Quantitative
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate ... - Caledonian Record
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization - GlobeNewswire
Big Money Moves: Is Funko Inc part of any ETFJuly 2025 Chart Watch & Fast Momentum Entry Tips - baoquankhu1.vn
Aug Wrap: Should you buy the dip on Rithm Acquisition Corp Debt Equity Composite UnitsWeekly Trade Analysis & Community Consensus Trade Alerts - baoquankhu1.vn
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):